Ibnsina Pharma (ISPH) reported a 40.72% year-on-year (YoY) increase in consolidated net profits attributable to the parent company for the first quarter (Q1) of 2026, hitting EGP 255.935 million, versus EGP 181.880 million.

Ibnsina Pharma announced cash dividend distribution valued at EGP 0.13 per share for 2025, according to a bourse disclosure.

Ibnsina Pharma (ISPH) generated consolidated net profits after tax and non-controlling interest valued at EGP 951.983 million in 2025, up by 54.9% from EGP 614.562 million in 2024.

The European Bank for Reconstruction and Development (EBRD) is providing EGP 1.3 billion, equivalent to €23.1 million, to Ibnsina Pharma (ISPH), to finance capital expenditure for a new warehouse and related long term working capital.

Ibnsina Pharma has exited from the financial leasing contracts related to the land and machinery within the Shorouk building.

Ibnsina Pharma (ISPH) recorded a 62.32% year-on-year (YoY) increase in consolidated net profits after tax and non-controlling interest in the first nine months of 2025 to EGP 659.843 million, versus EGP 406.513 million, the firm disclosed.

Ibnsina Pharma ranked first in non-pharma product distribution across pharmacies in Egypt during the first nine months of 2025.

Ibnsina Pharma announced a cash dividend distribution of EGP 0.160 per share, according to a bourse filing.

Ibnsina Pharma has retained its leading position among pharmaceutical distributors in Egypt, with a 31.1% market share in the first half (H1) of 2025, according to IQVIA reports.

Ibnsina Pharma generated consolidated net profits after tax and non-controlling interest valued at EGP 614.562 million in 2024

The European Bank for Reconstruction and Development (EBRD) has fully exited its remaining 8.8% equity in Ibnsina Pharma via the Egyptian Exchange (EGX)

Ibnsina Pharma witnessed a block-trading deal at a value of EGP 555.48 million, the Egyptian Exchange (EGX) announced

Ibnsina Pharma has ranked first among pharmaceutical distribution companies in Egypt for the second consecutive year

Ibnsina Pharma inked a new lease agreement with YANMU to enhance its sustainable and efficient supply chain solutions

Ibnsina Pharma (ISPH) recorded a 133.57% year-on-year (YoY) increase in consolidated net profits after tax and non-controlling interest in the first nine months of 2024 to EGP 406.513 million, versus EGP 174.037 million.

Ibnsina Pharma (ISPH) recorded a 68.4% year-on-year (YoY) increase in consolidated net profits after tax and non-controlling interest in the first half (H1) of 2024 to EGP 221.597 million, versus EGP 131.615 million.

Ibnsina Pharma (ISPH) reported a 35.3% year-on-year (YoY) increase in consolidated net profits attributable to the parent company for the first quarter (Q1) of 2024, hitting EGP 98.143 million, versus EGP 72.555 million.

Ibnsina Pharma (ISPH) reported a 23.8% year-on-year (YoY) increase in consolidated profits attributable to the parent company during 2023.

Ibnsina Pharma (ISPH) reported a 45.52% year-on-year (YoY) increase in consolidated profit attributable to the parent company during the first nine months of 2023.

Established in 2001, Ibnsina Pharma is the second-largest pharmaceutical distributor in Egypt, distributing products from over 350 global and local companies to more than 46,000 customers of pharmacies, hospitals, wholesalers, and healthcare institutions.